Marion T Kasaian

US Patent:

7501121, Mar 10, 2009

Filed:

Jun 17, 2005

Appl. No.:

11/155843

Inventors:

Lioudmila Tchistiakova - Andover MA, US
Marion T. Kasaian - Charlestown MA, US
Debra D. Donaldson - Medford MA, US
Xiang-Yang Tan - Reading MA, US
Davinder Gill - Burlington MA, US
Macy X. Jin - Reading MA, US
Bruce Jacobson - Framingham MA, US
Samuel J. Goldman - Acton MA, US
John Knopf - Carlisle MA, US
Angela M. Widom - Acton MA, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K 39/395
C07K 16/24

US Classification:

4241391, 5303879, 5303873

Abstract:

Agents (e. g. , antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.

US Patent:

7615213, Nov 10, 2009

Filed:

Jun 9, 2005

Appl. No.:

11/149309

Inventors:

Marion T. Kasaian - Charlestown MA, US
Lioudmila Tchistiakova - Andover MA, US
Geertruida M. Veldman - Sudbury MA, US
Kimberly Ann Marquette - Somerville MA, US
Xiang-Yang Tan - Reading MA, US
Debra D. Donaldson - Medford MA, US
Laura Long Lin - Weston MA, US
Tania Shane - Newton MA, US
Amy Sze Pui Tam - Medford MA, US
Eric Feyfant - Lexington MA, US
Nancy L. Wood - Somerville MA, US
Lori J. Fitz - Somerville MA, US
Angela M. Widom - Acton MA, US
Kevin D. Parris - Auburndale MA, US
Samuel J. Goldman - Acton MA, US
Jose W. Saldanha - Middlesex, GB

Assignee:

Wyeth - Madison NJ

International Classification:

A61K 39/395

US Classification:

4241331, 4241451, 5303873, 53038823

Abstract:

This application relates to antibodies, e. g. , humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e. g. , a human patient, one or more IL-13-associated disorders, e. g. , respiratory disorders (e. g. , asthma); atopic disorders (e. g. , allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e. g. , atopic dermatitis), and gastrointestinal organs (e. g. , inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.

US Patent:

7943342, May 17, 2011

Filed:

Jan 22, 2009

Appl. No.:

12/358111

Inventors:

Lioudmila Tchistiakova - Andover MA, US
Marion T. Kasaian - Cambridge MA, US
Debra D. Donaldson - Medford MA, US
Xiang-Yang Tan - Reading MA, US
Davinder Gill - Burlington MA, US
Macy X. Jin - Reading MA, US
Bruce Jacobson - Framingham MA, US
Samuel J. Goldman - Acton MA, US
John Knopf - Carlisle MA, US
Angela M. Widom - Acton MA, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

C12N 5/10
C12N 15/13
C12N 15/63

US Classification:

435 696, 4353201, 435325, 536 2353

Abstract:

Agents (e. g. , antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.

US Patent:

8221752, Jul 17, 2012

Filed:

Oct 8, 2009

Appl. No.:

12/575896

Inventors:

Marion T. Kasaian - Cambridge MA, US
Lioudmila Gennadievna Tchistiakova - Andover MA, US
Geertruida Machteld Veldman - Sudbury MA, US
Kimberly Ann Marquette - Somerville MA, US
Xiang-Yang Tan - Reading MA, US
Debra D. Donaldson - Medford MA, US
Laura Long Lin - Weston MA, US
Tania Shane - Newton MA, US
Amy Sze Pui Tam - Medford MA, US
Eric Feyfant - Lexington MA, US
Nancy L. Wood - Somerville MA, US
Lori J. Fitz - Somerville MA, US
Angela M. Widom - Acton MA, US
Kevin D. Parris - Auburndale MA, US
Samuel J. Goldman - Acton MA, US
Jose W. Saldanha - Enfield, GB

Assignee:

Wyeth LLC - Madison NJ

International Classification:

A61K 39/395

US Classification:

4241331, 4241581

Abstract:

This application relates to antibodies, e. g. , humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e. g. , a human patient, one or more IL-13-associated disorders, e. g. , respiratory disorders (e. g. , asthma); atopic disorders (e. g. , allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e. g. , atopic dermatitis), and gastrointestinal organs (e. g. , inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.

US Patent:

20030108549, Jun 12, 2003

Filed:

Oct 4, 2002

Appl. No.:

10/264634

Inventors:

Laura Carter - Medford MA, US
Beatriz Carreno - Acton MA, US
Leslie Lowe - Sudbury MA, US
Matthew Whitters - Hudson MA, US
Mary Collins - Natick MA, US
Margery Ma - Roxbury MA, US
Deborah Young - Melrose MA, US
JoAnn Witek - Acton MA, US
Glenn Larsen - Sudbury MA, US
Marion Kasaian - Charlestown MA, US
Debra Donaldson - Medford MA, US
Michelle Unger - Chapel Hill NC, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K039/395
A61K031/525
A61K031/4745
A61K031/415

US Classification:

424/145100, 514/251000, 514/291000, 514/406000

Abstract:

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

US Patent:

20040016010, Jan 22, 2004

Filed:

Apr 17, 2003

Appl. No.:

10/418450

Inventors:

Marion Kasaian - Cambridge MA, US
Matthew Whitters - Hudson MA, US
Andrea Wurster - Arlington MA, US
Mary Collins - Natick MA, US
Deborah Young - Melrose MA, US
Michael Grusby - Newton MA, US

International Classification:

A01K067/027

US Classification:

800/018000

Abstract:

A transgenic non-human mammal with a disruption in its IL-21 receptor gene is provided, along with methods of using the transgenic non-human mammal.

US Patent:

20050164323, Jul 28, 2005

Filed:

Dec 22, 2004

Appl. No.:

11/022327

Inventors:

Divya Chaudhary - Andover MA, US
Marion Kasaian - Charlestown MA, US
Cara Williams - Methuen MA, US
Suzana Marusic - Reading MA, US
Robert Czerwinski - North Grafton MA, US

Assignee:

Wyeth - Madison NJ

International Classification:

C12Q001/68
A61K038/00
C12N005/08
C12Q001/48

US Classification:

435015000, 514002000, 435372000

Abstract:

Methods for agents useful for treating asthma are disclosed. The methods include screening for agents that inhibit the production of a PKC-θ protein, as well as for agents that inhibit the kinase activity of a PKC-θ protein, or a functional fragment thereof, wherein such agents are useful for treating asthma. The methods also include screening for agents that inhibit the production of a reporter gene product encoded by a nucleic acid sequence operably linked to a PKC-θ promoter. Also disclosed are methods of treating asthma that include administering an agent that inhibits the production of a functional PKC-θ protein or the kinase activity of a PKC-θ protein or a functional fragment thereof. An isolated mast cell lacking expression of endogenous PKC-θ is also disclosed.

US Patent:

20060024268, Feb 2, 2006

Filed:

May 19, 2005

Appl. No.:

11/132947

Inventors:

Marion Kasaian - Charlestown MA, US
Debra Donaldson - Medford MA, US
Mary Collins - Natick MA, US
Nancy Wood - Somerville MA, US

International Classification:

A61K 38/20

US Classification:

424085200

Abstract:

An IL-21 polypeptide or other IL-21 pathway agonist can be used to treat atopic disorders, e.g., asthma.